HBSP (USA)
-
AXA Private Equity: The Diana Investment
Roberts, Michael J.; Sahlman, William A.Case HBS-812042-EEntrepreneurshipThe case focuses on an investment made by AXA Private Equity, a French manufacturer of food ingredients. The investment is made at the height of the financial markets, and financed with significant debt. Soon thereafter, the financial crisis impacted the company's financial performance, the valuation of all companies, and the balance sheet of banks. When the company breaches a covenant this set off a series of negotiations over the restructuring ...Starting at €8.20
-
Building an Integrated Biopharma Company: Crucell (A)
Hamermesh, Richard G.; Van Der Steen, Marianne; Harmeling, Susan S.Case HBS-815085-EEntrepreneurshipBy 2009, Crucell had become the largest biopharma company in the Netherlands and a symbol of national pride. The case traces the evolution of the company from a University spin-off into a fully-integrated company. Crucell's success, particularly in the vaccine space, had begun to attract the attention of much larger pharmaceutical companies. While there was much appeal to working with these companies, these relationships could also challenge Cruc...Starting at €8.20
-
Del Norte Paper Company (A) (Spanish Version)
Barrett, M. Edgar; Sahlman, William A.Case HBS-713S09Accounting and ControlSe ocupa de un problema de los precios de transferencia en una compleja situación internacional. Una amplia gama de temas están presentes en el caso, o son necesarios para un análisis caso a fondo. Tales problemas incluyen: costos relevantes; la adecuación de centros de beneficio; la idoneidad de la descentralización; transferencias de fondos internacionales; y la medición de la ganancia integrado.Starting at €8.20
-
Building an Integrated Biopharma Company: Crucell (B)
Hamermesh, Richard G.; Van Der Steen, Marianne; Harmeling, Susan S.Case HBS-815086-EEntrepreneurshipThe Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8 billion.Starting at €5.74